Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis-Reference-Cited by-同舟云学术

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

Published:2016-11-10 Issue:2 Volume:33 Page:175-183
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Fox Robert J.¹,Chan Andrew²,Zhang Annie³,Xiao James³,Levison Dane³,Lewin James B.³,Edwards Michael R.³,Marantz Jing L.³

Affiliation:

1. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA;

2. Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland;

3. Biogen, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2016.1248380

Reference29 articles.

1. Neurodegeneration in multiple sclerosis: novel treatment strategies

2. Current and emerging therapies in multiple sclerosis: a systematic review

3. Facilitating Medication Adherence in Patients with Multiple Sclerosis

4. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons;Journal of Comparative Effectiveness Research;2024-08-19

2. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-05

3. A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis;Journal of Managed Care & Specialty Pharmacy;2024-02-03

4. A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons;Value in Health;2023-11

5. Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina;Multiple Sclerosis and Related Disorders;2023-11